Henri Huttunen CSO of Herantis Pharma discusses the challenges of using neurotrophic factors as a treatment for Parkinson’s disease. Many successful drugs originate from molecules that already exist within the human body. Hormones, neurotransmitters and other endogenous molecules perform essential biological functions, making them attractive starting points for therapeutic development. If a molecule naturally supports a beneficial […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!